肝臟疾病

互動

閱讀原始引言

是的，我們與衛生部、馬利人民藥局（Pharmacie Populaire du Mali）以及國民議會合作。

Oui, auprès du ministère de la santé, pharmacie populaire du Mali, de l'assemblée nationale.

互動

閱讀原始引言

社區肝臟聯盟的倡議活動包括：與CMS（醫療保險和醫療補助服務中心）的互動、參與公眾意見徵詢機會（包括與醫療保險藥品價格談判相關的機會）、與政策制定者合作推動PBM（藥房福利管理機構）改革，以及向監管利益相關者宣導定價決策對慢性及罕見肝臟疾病患者的實際影響。

The Community Liver Alliance represents patient interests to regulators and policymakers responsible for advising on and determining drug pricing. We engage at the federal and state levels to ensure that the lived experiences of people affected by liver disease inform policy decisions related to drug access, affordability, and reimbursement. Our advocacy includes engagement with CMS, participation in public comment opportunities (including those related to Medicare Drug Price Negotiation), collaboration with policymakers on PBM reform, and education of regulatory stakeholders about the real-world impact of pricing decisions on patients with chronic and rare liver diseases. We elevate patient and caregiver voices to ensure pricing policies balance innovation with equitable and timely access to life-saving therapies.

行動與倡議

閱讀原始引言

每年，我們向中央政府及都道府縣政府提交下一財政年度的預算申請。

毎年、国や都道府県に対し次年度予算要望書を提出。

行動與倡議

閱讀原始引言

我們與 FDA [食品藥物管理局]、國會及白宮合作，共同推動影響肝病患者的聯邦政策。

We work with FDA, Congress, and the White House on federal policies that affect liver patients.